Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
ACUTE MYELOID LEUKEMIA-TYPE CHEMOTHERAPY FOR NEWLY-DIAGNOSED PATIENTSWITHOUT ANTECEDENT CYTOPENIAS HAVING MYELODYSPLASTIC SYNDROME AS DEFINED BY FRENCH-AMERICAN-BRITISH CRITERIA - A CANCER AND LEUKEMIA GROUP-B STUDY
Autore:
BERNSTEIN SH; BRUNETTE VL; DAVEY FR; WURSTERHILL D; MAYER RJ; STONE RM; SCHIFFER CA; BLOOMFIELD CD;
Indirizzi:
ROSWELL PK CANC INST,DIV MED,DEPT HEMATOL ONCOL & BONE MARROW TRANSPLANTAT,ELM & CARLTON STS BUFFALO NY 14263 SUNY SYRACUSE,HLTH SCI CTR SYRACUSE NY 13210 DANA FARBER CANC INST BOSTON MA 00000 UNIV MARYLAND BALTIMORE MD 00000 DARTMOUTH COLL SCH MED HANOVER NH 00000 CANC & LEUKEMIA GRP B LEBANON NH 00000
Titolo Testata:
Journal of clinical oncology
fascicolo: 9, volume: 14, anno: 1996,
pagine: 2486 - 2494
SICI:
0732-183X(1996)14:9<2486:AMLCFN>2.0.ZU;2-K
Fonte:
ISI
Lingua:
ENG
Soggetto:
ACUTE MYELOGENOUS LEUKEMIA; ACUTE NONLYMPHOCYTIC LEUKEMIA; SCORING SYSTEM; AGGRESSIVE CHEMOTHERAPY; PROGNOSTIC-SIGNIFICANCE; INTENSIVE CHEMOTHERAPY; REFRACTORY-ANEMIA; THERAPY; ADULTS; CLASSIFICATION;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
38
Recensione:
Indirizzi per estratti:
Citazione:
S.H. Bernstein et al., "ACUTE MYELOID LEUKEMIA-TYPE CHEMOTHERAPY FOR NEWLY-DIAGNOSED PATIENTSWITHOUT ANTECEDENT CYTOPENIAS HAVING MYELODYSPLASTIC SYNDROME AS DEFINED BY FRENCH-AMERICAN-BRITISH CRITERIA - A CANCER AND LEUKEMIA GROUP-B STUDY", Journal of clinical oncology, 14(9), 1996, pp. 2486-2494

Abstract

Purpose: To determine the treatment outcome of standard acute myeloidleukemia (AML)-type chemotherapy in a subset of patients with newly diagnosed myelodysplastic syndromes (MDS) compared with that of patients with de nova AML as defined using French-American-British (FAB) criteria. In addition, to determine the pretreatment variables having prognostic significance for treatment outcome in patients with MDS, Patients and Methods: Nine hundred seven newly diagnosed patients with no history of cytopenias having a local institutional de nova AML successfully karyotyped and treated on Cancer and Leukemia Group B (CALGB) protocols for AML from 1984 to 1992. Thirty-three of the 907 patients werereclassified as having MDS on central pathology review using FAB criteria and form the basis of this analysis. Results: The treatment outcomes for patients with MDS and AML were similar; the complete remission(CR) rate wets 79% and 68%, respectively (P = .37); median CR duration was 11 and 15 months, respectively (P = .28); and median survival wets 13 and 16 months, respectively (P = .72). for the MDS patients, there were no prognostic: variables for CR rate identified, For CR duration, only the Sanz classification had prognostic value. The prognostic:factors for survival in a univariate analysis included age, WBC count, Sanz classification, and percent blood blasts, In a proportional hazards analysis of survival, age greater than 60 years and WBC less than2.6 x 10(9)/L were adverse prognostic factors. Conclusion: In patients with no known history of cytopenias who are treated intensively at diagnosis, the FAB distinctions between MDS (refractory anemia with excess blasts and refractory anemia with excess blasts in transformation)and AML appear to have little therapeutic relevance. (C) 1996 by American Society of Clinical Oncology.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 27/09/20 alle ore 18:57:31